Advanced search
Publication Cover
International Medical Case Reports Journal Volume 14, 2021 - Issue
Submit an article Journal homepage
116
Views
2
CrossRef citations to date
0
Altmetric
Case Report

Role of Immunomodulation of BCG Therapy on AML Remission

Alice Kennedy1 Department of Internal Medicine, University of Massachusetts Medical School, Worcester, MA, 01655, USA
,
Kamal Kant Sahu2 Department of Internal Medicine, Saint Vincent Hospital, Worcester, MA, 01608, USAORCID Iconhttps://orcid.org/0000-0002-0382-6882
ORCID Icon &
Jan Cerny3 Division of Hematology and Oncology, Department of Internal Medicine, UMass Memorial Health Care, University of Massachusetts Medical School, Worcester, MA, 01655, USACorrespondence[email protected]
Pages 115-119 | Published online: 25 Feb 2021

References

  • Mathé G, Amiel JL, Schwarzenberg L, et al. Active immunotherapy for acute lymphoblastic leukaemia. Lancet. 1969;1(7597):697–699. doi:10.1016/s0140-6736(69)92648-8
  • Morton DL, Eilber FR, Holmes EC, et al. BCG immunotherapy of malignant melanoma: summary of a seven year experience. Ann Surg. 1974;180(4):635–643. doi:10.1097/00000658-197410000-00029
  • Han RF, Pan JG. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology. 2006;67(6):1216–1223. doi:10.1016/j.urology.2005.12.014
  • Sylvester RJ, van der M, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168(5). doi:10.1097/01.JU.0000034450.80198.1C
  • Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF. Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol. 1992;147(6):1636–1642. doi:10.1016/S0022-5347(17)37668-1
  • Alhunaidi O, Zlotta AR. The use of intravesical BCG in urothelial carcinoma of the bladder. Ecancermedicalscience. 2019;13. doi:10.3332/ecancer.2019.905.
  • Anguille S, Van Tendeloo VF, Berneman ZN. Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia. Leukemia. 2012;26(10):2186–2196. doi:10.1038/leu.2012.145
  • Teague RM, Kline J. Immune evasion in acute myeloid leukemia: current concepts and future directions. J Immunother Cancer. 2013;1(1):1. doi:10.1186/2051-1426-1-13
  • Lal A, Sahu KK, Jindal V, Mishra AK, Siddiqui AD. Role of immunotherapy in metastatic renal cell cancer: past, present and future. Ann Transl Med. 2019;7(S8):S349–S349. doi:10.21037/atm.2019.09.95
  • Akamat AMK, Org M, Kamat AM, et al. Expert consensus document: consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. Nat Rev Urol. 2015;12:225–235. doi:10.1038/nrurol.2015.58
  • Morales A. BCG: a throwback from the stone age of vaccines opened the path for bladder cancer immunotherapy. Can J Urol. 2017;24(3):8788–8793.
  • Buffen K, Oosting M, Quintin J, et al. Autophagy controls BCG-induced trained immunity and the response to intravesical BCG therapy for bladder cancer. PLoS Pathog. 2014;10(10):e1004485. doi:10.1371/journal.ppat.1004485
  • Kleinnijenhuis J, Quintin J, Preijers F, et al. Bacille Calmette-Guérin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci U S A. 2012;109(43):17537–17542. doi:10.1073/pnas.1202870109
  • Zhao W, Schorey JS, Groger R, Allen PM, Brown EJ, Ratliff TL. Characterization of the fibronectin binding motif for a unique mycobacterial fibronectin attachment protein, FAP. J Biol Chem. 1999;274(8):4521–4526. doi:10.1074/jbc.274.8.4521
  • Joseph M, Enting D. Immune responses in bladder cancer-role of immune cell populations, prognostic factors and therapeutic implications. Front Oncol. 2019;9:1270. doi:10.3389/fonc.2019.01270
  • Sahu KK, Mishra AK, Lal A, Abraham GM. Mycobacterium Avium Complex: A Rare Cause of Pancytopenia in HIV Infection. J Microsc Ultrastruct. 2019;8(1):27–30
  • Petropoulou AD, Lapusan S, Marie JP, Rio B. Intravesical Bacillus Calmette-Guérin for the treatment of superficial bladder cancer following hematopoietic stem cell transplantation. Leuk Lymphoma. 2008;49(8):1627–1629. doi:10.1080/10428190802136376
  • Ohnishi K, Yamanishi H, Naito K, et al. Reconstitution of peripheral blood lymphocyte subsets in the long-term disease-free survivors of patients with acute myeloblastic leukemia. Leukemia. 1998;12(1):52–58. doi:10.1038/sj.leu.2400891
  • Greiner J, Götz M, Bunjes D, Hofmann S, Wais V. Immunological and clinical impact of manipulated and unmanipulated DLI after allogeneic stem cell transplantation of AML patients. J Clin Med. 2019;9(1):39. doi:10.3390/jcm9010039
  • Hofmann S, Götz M, Schneider V, et al. Donor lymphocyte infusion induces polyspecific CD8 + T-cell responses with concurrent molecular remission in acute myeloid leukemia with NPM1 mutation. J Clin Oncol. 2013;31(3):e44–e47. doi:10.1200/JCO.2011.41.1116
  • Maywald O, Buchheidt D, Bergmann J, et al. Spontaneous remission in adult acute myeloid leukemia in association with systemic bacterial infection – case report and review of the literature. Ann Hematol. 2004;83(3):189–194. doi:10.1007/s00277-003-0741-y
  • Adams S. Toll-like receptor agonists in cancer therapy. Immunotherapy. 2009;1(6):949–964. doi:10.2217/imt.09.70

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.